No meaningful signal from this cluster, the sales are minor and likely part of pre-arranged 10b5-1 plans; the rest are standard compensation events. Traders should focus on clinical or regulatory developments rather than this activity.
ALNY drugs
ALNY drug pipeline →- ● brezosiran 3/10 Phase 1b
- ● GIVLAARI 3/10 Approved (FDA approval 2019-11-20)
- ● ONPATTRO 3/10 Approved (marketed); Phase 3 (APOLLO-B) completed
- ● OXLUMO 3/10 Approved
- ● ALN-6222 2/10 unknown (no registered ClinicalTrials.gov record found; appears to be an early, minimally disclosed pipeline program)
- 2 more · All ALNY drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 3 $318.65entry
- T+1 · 9mo ago +2.71%α +1.95% · $327.30
- T+5 · 8mo ago +1.17%α +1.65% · $322.38
- T+20 · 8mo ago +3.83%α +8.24% · $330.87
- T+60 · 6mo ago −7.22%α −17.54% · $295.63
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
A cluster of insider transactions at Alnylam Pharmaceuticals over the past week includes open-market sales by the CSO and EVP of R&D totaling $204K, alongside non-cash grant and derivative exercise events involving top executives including the CEO and CFO. The sales are small in absolute value and represent a negligible fraction of the company's $43.4B market cap, while the other transactions are routine equity compensation activities.
Key Financial Metrics
Key Facts
- CSO Kevin Fitzgerald sold $91,483 in shares (289 shares at $316.55) on March 3, 2026
- EVP of R&D Pushkal Garg sold $112,443 in shares (355 shares at $316.74) on March 3, 2026
- CEO Yvonne Greenstreet received a non-cash award of 13,844 shares and exercised 5,921 shares via derivative on February 27 and March 2
- CFO Jeffrey Poulton and other C-suite executives received non-cash awards and exercised derivatives with no open-market impact
- Total open-market sales in cluster: $204K, representing just 0.0005% of Alnylam's $43.4B market cap
Financial Impact
$204K in open-market sales, 0.0005% of market cap, immaterial
Risk Factors
- Perception of insider selling ahead of a potential downturn, though magnitude is too small to support concern
- Future dilution from equity grants, though typical for biotech firms
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (10 trades, 7d window) | cluster-ALNY-1772673102389 |
Track record
15 reports on ALNY
1 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +26.35% at T+5 after the Oct 23, 2026 report. 1 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $160.53 Now $159.73 −0.50% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $165.50 Now $159.73 −3.49% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $165.04 Now $159.73 −3.22% settles Nov 20
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $165.04 Now $159.73 −3.22% settles Nov 20
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $156.66 to $156.65 Now $159.73 +1.96% ▼ −0.01% −3.30% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $156.66 to $156.65 Now $159.73 +1.96% ▼ −0.01% −3.30% vs SPY
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $165.00 to $155.94 Now $159.73 −3.19% ▼ −5.49% −2.79% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $174.00 to $156.66 Now $159.73 −8.20% ▼ −9.97% −5.24% vs SPY
- Oct 23, 202624d ago Institutional Cluster Bearish 4/10 Entry $224.03 to $165.00 Now $159.73 +28.70% ▲ +26.35% +25.79% vs SPY
- Aug 17, 202613w ago Court Ruling Neutral 4/10 Entry $228.61 to $240.08 Now $159.73 −30.13% ▲ +5.02% +5.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers